IRF8 and glycogen storage disease VI: In contrast, another patient with a different novel, de novo heterozygous IRF8 variant (c.10C>T) had milder early life infection susceptibility, but no lymphoproliferation, nor immune-mediated organ disease, and no prior exposure to BCG vaccine.